
Clinical Trial Confirms Keytruda and Lenvima Benefit in Kidney Cancer
Updated results from the phase 2 KEYNOTE-B61 trial showed that combining Keytruda (pembrolizumab) with Lenvima (lenvatinib) continued to help shrink tumors and improve survival when used as a first treatment for people with advanced non-clear cell kidney …